Hyper Hep B Mechanism of Action

Pharmacology: Hepatitis B immune globulin (human) provides passive immunization for individuals exposed to the hepatitis B virus (HBV) as evidenced by a reduction in the attack rate of hepatitis B following its use. The administration of the usual recommended dose of this immune globulin generally results in a detectable level of circulating anti-HBs which persists for approximately ≥2 months. The highest antibody (IgG) serum levels were seen in the following distribution of subjects studied: Day 3: 38%; day 7: 41.7%; day 14: 11.1%; day 21: 8.3%. Mean values of half-life were between 17.5 and 25 days, with the shortest being 5.9 days and the longest 35 days.
Cases of type B hepatitis are rarely seen following exposure to HBV in persons with preexisting anti-HBs. No confirmed instance of transmission of hepatitis B has been associated with Hyper Hep B.
In a clinical study in 8 healthy human adults receiving another hyperimmune immune globulin product treated with solvent/detergent, rabies human immune globulin, BayRab, prepared by the same manufacturing process, detectable passive antibody titers were observed in the serum of all subjects by 24 hrs post-injection and persisted through the 21-day study period. These results suggest that passive immunization with immune globulin products is not affected by the solvent/detergent treatment.